Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Omeprazole Isomer Data Based On AaiPharma Patents Submitted To FDA

Executive Summary

AaiPharma is submitting data to FDA regarding the isomer content of omeprazole (AstraZeneca's Prilosec) based on patents recently issued to the company.

You may also be interested in...



Sanofi Plavix Patent On Polymorphic Form Covers Currently Marketed Product

Sanofi-Synthelabo's latest patent for its antithrombotic Plavix covers the polymorphic form of clopidogrel that is currently marketed in the U.S., the company said

Sanofi Plavix Patent On Polymorphic Form Covers Currently Marketed Product

Sanofi-Synthelabo's latest patent for its antithrombotic Plavix covers the polymorphic form of clopidogrel that is currently marketed in the U.S., the company said

Prilosec Generics Stability Review By FDA To Be Completed By Mid-November

FDA expects to complete its review of data submitted by AstraZeneca regarding the long-term stability of omeprazole generics in a month.

Related Content

UsernamePublicRestriction

Register

PS038450

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel